Drug Trial Radar · NCT02553317
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Nov 2015
Primary completion
Aug 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- Ablynx, a Sanofi companyIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis
Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
Interventions
CaplacizumabBiological
* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day. * Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE. * Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.
PlaceboBiological
* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day. * Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE. * Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Platelet Count ResponseTime frame: Only data from the DB daily PE period (median = 5 days) up to the cut-off were used. The cut-off point was defined by whichever occured first: 1) 45 days of daily PE after start of study drug, 2) stop of daily PE, 3) stop of study drug (median = 34 days)
Locations
101 sites in 16 countries. Site status is shown where the registry gives one.
Investigator Site
Birmingham, Alabama
Investigator Site
Los Angeles, California
Investigator Site
Atlanta, Georgia
Investigator Site
Boston, Massachusetts
Investigator Site
St Louis, Missouri
Investigator Site
Rochester, New York
Investigator Site
Rochester, New York
Investigator Site
Valhalla, New York
Investigator Site
Chapel Hill, North Carolina
Investigator Site
Durham, North Carolina
Investigator Site
Winston-Salem, North Carolina
Investigator SIte
Cleveland, Ohio
Investigator Site
Columbus, Ohio
Investigator Site
Oklahoma City, Oklahoma
Investigator Site
Pittsburgh, Pennsylvania
Investigator Site
Charleston, South Carolina
Investigator Site
Greenville, South Carolina
Investigator Site
Houston, Texas
Investigator Site
Salt Lake City, Utah
Investigator Site
Brisbane, Australia
Investigator Site 1
Melbourne, Australia
Investigator Site 2
Melbourne, Australia
Investigator Site 3
Melbourne, Australia
Investigator Site 4
Melbourne, Australia
Investigator Site 5
Melbourne, Australia
Investigator Site
Perth, Australia
Investigator Site 1
Sydney, Australia
Investigator Site 2
Sydney, Australia
Investigator Site
Vienna, Austria
Investigator Site
Antwerp, Belgium
Investigator Site
Brussels, Belgium
Investigator Site
Haine-Saint-Paul, Belgium
Investigator Site
La Louvière, Belgium
Investigator Site
Leuven, Belgium
Investigator Site
London, Canada
Investigator Site
Toronto, Canada
Invesigator Site
Montreal, Quebec, Canada
Investigator Site
Brno, Czechia
Investigator Site
Hradec Králové, Czechia
Investigator Site
Olomouc, Czechia
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.